Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sage Gets More Time For Zulresso Launch Preparations With Delay Of US FDA Approval

Executive Summary

After an advisory committee recommended approval for the postpartum depression treatment if administered under a REMS program at certified centers, Sage submitted a proposed REMS, causing the agency to extend the PDUFA date three months.

Advertisement

Related Content

Sage May Be Forced To Simplify Brexanolone Dosing Regimen
Sage's Postpartum Depression Drug Brexanolone Faces Loss-Of-Consciousness Questions
Sage's Oral GABA-A Modulator Shows 'Dramatic' Effect On Depression
All Smiles At Sage As Phase III Postpartum Depression Data Are Positive

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124205

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel